BETOPTIC 0.5 %w/v Eye Drops Solution Airija - anglų - HPRA (Health Products Regulatory Authority)

betoptic 0.5 %w/v eye drops solution

novartis pharmaceuticals uk ltd - betaxolol hydrochloride - eye drops solution - 0.5 %w/v - beta blocking agents

BETOPTIC SUSPENSION SINGLE DOSE Airija - anglų - HPRA (Health Products Regulatory Authority)

betoptic suspension single dose

novartis ireland limited - betaxolol hydrochloride - eye drops suspension - 0.25 %w/v - betaxolol

BETOPTIC S- betaxolol hydrochloride suspension/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

betoptic s- betaxolol hydrochloride suspension/ drops

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betaxolol hydrochloride 2.8 mg in 1 ml - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

BETOPTIC S- betaxolol hydrochloride suspension/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

betoptic s- betaxolol hydrochloride suspension/ drops

novartis pharmaceuticals corporation - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

Betoptic 5 mg/ml eye drops sol. dropper cont. Belgija - anglų - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

betoptic 5 mg/ml eye drops sol. dropper cont.

novartis pharma sa-nv - betaxolol hydrochloride 5,6 mg/ml - eq. betaxolol 5 mg/ml - eye drops, solution - 5 mg/ml - betaxolol hydrochloride 5.6 mg/ml - betaxolol

betoptic- betaxolol hydrochloride solution/ drops Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

betoptic- betaxolol hydrochloride solution/ drops

alcon - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - solution/ drops - 5.6 mg in 1 ml - betoptic ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. it may be used alone or in combination with other anti-glaucoma drugs. in clinical studies betoptic was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. however, caution should be used in treating patients with severe reactive airway disease or a history of asthma. hypersensitivity to any component of this product. betoptic ophthalmic solution is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.

Betoptic Eye Drops 0.5% Australija - anglų - Department of Health (Therapeutic Goods Administration)

betoptic eye drops 0.5%

alcon laboratories australia pty ltd - betaxolol hydrochloride -

BETOPTIC Eye Drops Solution 0.5 %w/v Airija - anglų - HPRA (Health Products Regulatory Authority)

betoptic eye drops solution 0.5 %w/v

pco manufacturing - betaxolol hydrochloride - eye drops solution - 0.5 %w/v

BETOPTIC Eye Drops Solution 0.5 %w/v Airija - anglų - HPRA (Health Products Regulatory Authority)

betoptic eye drops solution 0.5 %w/v

eurodrug ltd - betaxolol hydrochloride - eye drops solution - 0.5 %w/v

BETOPTIC Eye Drops Solution 0.5 %w/v Airija - anglų - HPRA (Health Products Regulatory Authority)

betoptic eye drops solution 0.5 %w/v

g & a licensing limited - betaxolol hydrochloride - eye drops solution - 0.5 %w/v